|
|Section2= |Section3= }} Zibotentan (INN) (earlier code name ZD4054) is an anti-cancer candidate.〔(【引用サイトリンク】title=Drugs of the Future )〕 It is an endothelin receptor antagonist. It failed a phase III clinical trial for prostate cancer〔http://www.fiercebiotech.com/story/azs-zibotentan-flunks-late-stage-prostate-cancer-trial/2010-09-27〕 but other trials are planned.〔http://www.genengnews.com/gen-news-highlights/pfizer-astrazeneca-and-actelion-separately-report-phase-iii-trial-failures/81243985/〕 Tolerability of zibotentan plus docetaxel has been evaluated. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Zibotentan」の詳細全文を読む スポンサード リンク
|